Literature DB >> 2426299

Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush.

I Norheim, E Theodorsson-Norheim, E Brodin, K Oberg.   

Abstract

The plasma concentrations of various tachykinins were measured before and during flushing episodes in 16 patients with metastatic carcinoid tumors. The flushing attacks were induced by iv injection of pentagastrin or ingestion of food or alcohol. Tachykinins, such as neurokinin A (NKA) and neuropeptide K (NPK), increased 2-fold during flushing episodes in 12 patients, and the plasma concentrations of substance P increased to a varying extent in 3 patients. Chromatographic analysis of plasma samples taken before and during flushing episodes in 2 patients indicated the presence of individual spectra of tachykinins. In addition, the plasma concentration of tachykinin [TKLI(K12)], using an assay that detects NKA, NPK, kassinin, eledoisin, and NKB, but not substance P and physalaemin, and the urinary excretion of 5-hydroxyindole acetic acid (5-HIAA) were measured in 20 patients with midgut carcinoid tumors before and during treatment with human leucocyte interferon. The overall changes in the 2 tumor markers were concordant in 18 of the 20 patients. Thus, the Spearman correlation coefficient between the percent changes in urinary 5-hydroxyindole acid excretion and plasma TKLI(K12) was 0.54 (P less than 0.001). The patients who had a decrease in the tumor markers also had a decrease in flushing episodes and diarrhea. Plasma TKLI(K12) is a convenient tumor marker for the diagnosis and follow-up of patients with carcinoid tumors of midgut origin. The combined use of both tumor markers strengthens the diagnosis and may improve the evaluation of response during treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2426299     DOI: 10.1210/jcem-63-3-605

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

2.  Tachykinins stimulate lipid peroxidation mediated by free radicals in gastrointestinal tract of rat.

Authors:  M Lördal; O Söder; P M Hellström
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

3.  Occult retroperitoneal carcinoid tumor with flushing and solitary lung metastasis.

Authors:  J A Jackson; H D Shipman
Journal:  West J Med       Date:  1989-10

4.  Malignant carcinoid tumors. An analysis of 103 patients with regard to tumor localization, hormone production, and survival.

Authors:  I Norheim; K Oberg; E Theodorsson-Norheim; P G Lindgren; G Lundqvist; A Magnusson; L Wide; E Wilander
Journal:  Ann Surg       Date:  1987-08       Impact factor: 12.969

5.  Two cases of gastric carcinoids: diagnostic and therapeutic aspects.

Authors:  H Ahlman; A Dahlström; L Enerbäck; G Granérus; O Nilsson; S Persson; L E Tisell
Journal:  World J Surg       Date:  1988-06       Impact factor: 3.352

6.  Neuropeptide K potently stimulates salivary gland secretion and potentiates substance P-induced salivation.

Authors:  Y Takeda; J E Krause
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

7.  Secretory patterns of tryptophan metabolites in midgut carcinoid tumor cells.

Authors:  G Westberg; H Ahlman; O Nilsson; A Illerskog; B Wängberg
Journal:  Neurochem Res       Date:  1997-08       Impact factor: 3.996

8.  Effect of a long-acting somatostatin analogue (octreotide) on circulating tachykinins and the pentagastrin-induced carcinoid flush.

Authors:  H J Balks; J M Conlon; W Creutzfeldt; F Stöckmann
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine.

Authors:  M Lördal; G Navalesi; E Theodorsson; C A Maggi; P M Hellström
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

Review 10.  The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid.

Authors:  W P Tormey; R J FitzGerald
Journal:  Postgrad Med J       Date:  1995-09       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.